Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLA-SE in Merkel Cell Carcinoma
NCT02035657Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GLA-SE adjuvant in Merkel cell carcinoma (MCC), sponsored by Merck & Co. Primary endpoint: Safety and feasibility at 1 year. Started Jan 2014; status: completed.
02
Drugs
GLA-SE adjuvant
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT02035657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035657.